The S&P 500 fell nearly 10% in June 2008, and investors began to brace for an eventual market crash later in the year. That was also a time when companies sealed the hatches and girded for tough days ahead, in many instances eliminating dividends that ...

Below is a chart of Boeing Co. versus Gilead Sciences, Inc. plotting their respective size rank within the S&P 500 over time (BA plotted in blue; GILD plotted in green): Loading+chart+�+2013+TickerTech.

Gilead Sciences, Inc. (NASDAQ:GILD) In parallel with the development of more effective HIV treatments, researchers are also making tremendous progress in the prevention of this disease.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the Wells Fargo Securities 2013 Healthcare Conference in Boston.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from a single-arm, open-label Phase 2 study (Study 101-09) evaluating idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of ...

Gilead Sciences, Inc. (NASDAQ:GILD) was in 63 hedge funds' portfolio at the end of March. GILD shareholders have witnessed an increase in hedge fund sentiment of late.

This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on.

Gilead Sciences, Inc. : Gilead Sciences to Present at the Goldman Sachs 34th Annual Healthcare Conference on Tuesday, June 11.

Today, Wall Street Reports announced new research reports highlighting ResMed Inc. (NYSE: RMD), Quest Diagnostics Inc. (NYSE: DGX), Mettler-Toledo International, Inc. (NYSE: MTD), Gilead Sciences, Inc. (NASDAQ: GILD), and TearLab Corporation ...

Gilead Sciences, Inc. (GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.